Moderna
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Moderna R&D Day Highlights Progress and Strategic Priorities
Moderna announces 10 product approvals by 2027, including next-gen COVID and flu/COVID combo vaccines for 2024 submission, positive Phase 3 results for RSV vaccine for high-risk adults, and norovirus vaccine advancing to Phase 3. The company plans to reduce R&D expense by $1.1 billion and extend financial framework through 2028.
Moderna expects up to $3.5B in 2025 sales
Moderna delays break-even goal to 2028, expects 2025 sales below 2024 forecast, and cuts R&D costs by $1.1 billion starting 2026. The company anticipates meaningful revenue from 10 new product approvals in 2028, reflecting uncertainty in COVID and RSV markets. Moderna plans to submit an FDA application for RSV shot expansion and focus on a COVID-influenza combination shot.
Moderna expects up to $3.5 billion in 2025 sales
Moderna forecasts $2.5-$3.5 billion in sales for 2024, with 25% annual revenue growth from 2026-2028 driven by new product launches. The company plans to submit an FDA application to expand RSV shot approval to high-risk adults under 60, and is focusing on a COVID-flu combination shot. Moderna's mRESVIA met immune-response targets in a new study, and the company plans to launch a flu vaccine efficacy study this year.
Moderna to cut $1.1 billion in costs and launch 10 new products by 2027 as it charts post
The article discusses the use of SSR (Server-Side Rendering) and its implementation through a specific JavaScript file, emphasizing its role in enhancing web performance and user experience.
Moderna R&D day: $1 billion in cost cuts, 10 product launches planned
Moderna plans to cut $1.1 billion in expenses by 2027 and expects 10 new product approvals, including vaccines for RSV, flu, and norovirus, while pausing some R&D projects. The company aims for $3.6-3.8 billion in R&D spending by 2027, down from $4.8 billion expected this year, and targets a 25%+ CAGR from 2026 to 2028.
Moderna slashes research spending, trims pipeline as it looks to regain footing
Moderna plans to file for three vaccine approvals by year-end, cutting R&D spending by 20% and dropping five drug candidates from its pipeline. The company aims for 10 approvals by 2027, focusing on critical vaccines like next-gen COVID, flu-COVID combo, and RSV for high-risk adults under 60.
Moderna touts research progress as it cuts R&D spending by $1.1 billion
Moderna to cut R&D spending by 23% ($1.1 billion) from 2024-2027, focusing on nine late-stage development medicines, aiming for $6 billion in annual sales by 2028.
GSK Abandons Herpes Vaccine After Disappointing Phase I/II Proof-of-Concept Data
GSK discontinues early-stage herpes simplex virus vaccine development after failing TH HSV REC-003 proof-of-concept study. No safety concerns were found, and GSK will continue to collect data for future research. Moderna and BioNTech are advancing their own HSV vaccines.
Use of COVID-19 Vaccines for Persons Aged ≥6 Months
ACIP recommended 2024–2025 COVID-19 vaccination with FDA-approved vaccines for all persons aged ≥6 months, targeting currently circulating SARS-CoV-2 strains, including Omicron JN.1 lineage (JN.1 and KP.2), to provide additional protection against severe COVID-19–associated illness and death.
© Copyright 2025. All Rights Reserved by MedPath